Grace Therapeutics: 10% owner Opaleye Management Inc. bought 87,801 shares

What happened Opaleye Management Inc., identified as a 10% owner, reported two open-market purchases of Grace Therapeutics shares. The filing shows 21,390 shares purchased on Oct 22, 2026 at a weighted average price of $1.93 for $41,193, and 66,411 shares purchased on Oct 26, 2026 at a weighted average price of $1.77 for $117,408 — a total of 87,801 shares for $158,601.

Key details

• Transaction dates and prices: Oct 22, 2026 — 21,390 shares at $1.93 (weighted avg; range $1.91–$1.93 per footnote); Oct 26, 2026 — 66,411 shares at $1.77 (weighted avg; range $1.705–$1.79 per footnote).
• Shares owned after the transaction: not specified in the provided filing.
• Footnotes: F1 notes the securities are owned directly by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager and may be deemed to beneficially own the Fund's securities; F2 and F3 explain the reported prices are weighted averages across multiple trades and offer to provide breakdowns on request; F4 contains a disclaimer that Opaleye Management Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.
• Transaction code: P (purchase / open-market or private purchase).

Why it may matter

• The filing reports purchases by a 10% owner (a large holder, not an executive), not option exercises, gifts, or tax withholding events.
• The Form 4 shows the trades and the amounts but does not state the reasons for them. A filing does not show why the insider traded or why the company acted.